313 related articles for article (PubMed ID: 35156888)
21. Biomarkers in Inflammatory Bowel Diseases: Predicting the Indication and the Effect of Biologics.
Tarapatzi G; Filidou E; Kandilogiannakis L; Vradelis S; Kolios G
J Gastrointestin Liver Dis; 2022 Jun; 31(2):229-243. PubMed ID: 35694983
[TBL] [Abstract][Full Text] [Related]
22. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities.
Plevris N; Lees CW
Gastroenterology; 2022 Apr; 162(5):1456-1475.e1. PubMed ID: 35101422
[TBL] [Abstract][Full Text] [Related]
23. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
[TBL] [Abstract][Full Text] [Related]
24. An Update on Herbal Products for the Management of Inflammatory Bowel Disease.
Arya H; Dass R; Chopra B; Kriplani P; Deswal G; Singh Grewal A; Dhingra AK; Kumar S
Antiinflamm Antiallergy Agents Med Chem; 2023; 22(1):1-9. PubMed ID: 37497699
[TBL] [Abstract][Full Text] [Related]
25. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.
Arrigo S; Alvisi P; Banzato C; Bramuzzo M; Celano R; Civitelli F; D'Arcangelo G; Dilillo A; Dipasquale V; Felici E; Fuoti M; Gatti S; Knafelz D; Lionetti P; Mario F; Marseglia A; Martelossi S; Moretti C; Norsa L; Panceri R; Renzo S; Romano C; Romeo E; Strisciuglio C; Martinelli M
Dig Liver Dis; 2021 Mar; 53(3):283-288. PubMed ID: 33388247
[TBL] [Abstract][Full Text] [Related]
26. Surgery for Inflammatory Bowel Disease in the Era of Biologics.
Lightner AL
J Gastrointest Surg; 2020 Jun; 24(6):1430-1435. PubMed ID: 32253646
[TBL] [Abstract][Full Text] [Related]
27. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
Franceschet I; Cazzagon N; Del Ross T; D'Incà R; Buja A; Floreani A
Eur J Gastroenterol Hepatol; 2016 May; 28(5):508-13. PubMed ID: 26872110
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate for inflammatory bowel disease: time for reconsideration.
Nielsen OH; Ainsworth MA; Steenholdt C
Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
[No Abstract] [Full Text] [Related]
29. Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series.
Ayoub A; Jairath V; Aldraiweesh S; Khanna R; Gregor J; Chande N
Inflamm Bowel Dis; 2020 Nov; 26(12):e157-e158. PubMed ID: 32651999
[No Abstract] [Full Text] [Related]
30. Advances in inflammatory bowel diseases in children.
Michail S; Ramsy M; Soliman E
Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the French Vasculitis Study Group.
Humbert S; Guilpain P; Puéchal X; Terrier B; Rivière S; Mahr A; Pagnoux C; Bagnères D; Cordier JF; Le Quellec A; Altwegg R; Guillevin L;
Rheumatology (Oxford); 2015 Nov; 54(11):1970-5. PubMed ID: 26106214
[TBL] [Abstract][Full Text] [Related]
32. [Role of anti-TNF therapy (biologics) in the treatment of chronic inflammatory bowel disease in children].
Kolacek S
Acta Med Croatica; 2013 Apr; 67(2):89-92. PubMed ID: 24471292
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory bowel disease.
Knigge KL
Clin Cornerstone; 2002; 4(4):49-60. PubMed ID: 12739326
[TBL] [Abstract][Full Text] [Related]
34. Obesity and novel management of inflammatory bowel disease.
Kim JH; Oh CM; Yoo JH
World J Gastroenterol; 2023 Mar; 29(12):1779-1794. PubMed ID: 37032724
[TBL] [Abstract][Full Text] [Related]
35. Prognosticating the Course of Inflammatory Bowel Disease.
Koliani-Pace JL; Siegel CA
Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):395-404. PubMed ID: 31078243
[TBL] [Abstract][Full Text] [Related]
36. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
[TBL] [Abstract][Full Text] [Related]
37. Assessing disease activity and disease activity indices for inflammatory bowel disease.
Xiao Li F; Sutherland LR
Curr Gastroenterol Rep; 2002 Dec; 4(6):490-6. PubMed ID: 12441039
[TBL] [Abstract][Full Text] [Related]
38. Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBD.
Picoraro JA; Lee D; Heller CA; Weaver A; Hyams JS; Conklin LS; Otley A; Ziring D; Kugathasan S; Rosh JR; Mulberg A; Denson LA; Kappelman MD; Grossman AB; Bousvaros A; Park KT
Inflamm Bowel Dis; 2019 Jan; 25(1):27-32. PubMed ID: 29931102
[TBL] [Abstract][Full Text] [Related]
39. Time to Revisit Disease Classification in Inflammatory Bowel Disease: Is the Current Classification of Inflammatory Bowel Disease Good Enough for Optimal Clinical Management?
Verstockt B; Bressler B; Martinez-Lozano H; McGovern D; Silverberg MS
Gastroenterology; 2022 Apr; 162(5):1370-1382. PubMed ID: 34995534
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
Wu JF
Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
